Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family - PubMed (original) (raw)
doi: 10.1158/1535-7163.MCT-10-0976. Epub 2011 Mar 25.
Kirsty Ratcliffe, Zena Wilson, Neil H James, Sue Ashton, Anna Wainwright, Jane Kendrew, Philippa Dudley, Nicola Broadbent, Graham Sproat, Sian Taylor, Claire Barnes, Jeffrey C Silva, Charles L Farnsworth, Laurent Hennequin, Donald J Ogilvie, Juliane M Jürgensmeier, Masabumi Shibuya, Stephen R Wedge, Simon T Barry
Affiliations
- PMID: 21441409
- DOI: 10.1158/1535-7163.MCT-10-0976
Free article
Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family
Sandra R Brave et al. Mol Cancer Ther. 2011 May.
Free article
Abstract
Cediranib is a potent inhibitor of the VEGF receptor (VEGFR)-2 and VEGFR-3 tyrosine kinases. This study assessed the activity of cediranib against the VEGFR-1 tyrosine kinase and the platelet-derived growth factor receptor (PDGFR)-associated kinases c-Kit, PDGFR-α, and PDGFR-β. Cediranib inhibited VEGF-A-stimulated VEGFR-1 activation in AG1-G1-Flt1 cells (IC(50) = 1.2 nmol/L). VEGF-A induced greatest phosphorylation of VEGFR-1 at tyrosine residues Y1048 and Y1053; this was reversed by cediranib. Potency against VEGFR-1 was comparable with that previously observed versus VEGFR-2 and VEGFR-3. Cediranib also showed significant activity against wild-type c-Kit in cellular phosphorylation assays (IC(50) = 1-3 nmol/L) and in a stem cell factor-induced proliferation assay (IC(50) = 13 nmol/L). Furthermore, phosphorylation of wild-type c-Kit in NCI-H526 tumor xenografts was reduced markedly following oral administration of cediranib (≥1.5 mg/kg/d) to tumor-bearing nude mice. The activity of cediranib against PDGFR-β and PDGFR-α was studied in tumor cell lines, vascular smooth muscle cells (VSMC), and a fibroblast line using PDGF-AA and PDGF-BB ligands. Both receptor phosphorylation (IC(50) = 12-32 nmol/L) and PDGF-BB-stimulated cellular proliferation (IC(50) = 32 nmol/L in human VSMCs; 64 nmol/L in osteosarcoma cells) were inhibited. In vivo, ligand-induced PDGFR-β phosphorylation in murine lung tissue was inhibited by 55% following treatment with cediranib at 6 mg/kg but not at 3 mg/kg or less. In contrast, in C6 rat glial tumor xenografts in mice, ligand-induced phosphorylation of both PDGFR-α and PDGFR-β was reduced by 46% to 61% with 0.75 mg/kg cediranib. Additional selectivity was showed versus Flt-3, CSF-1R, EGFR, FGFR1, and FGFR4. Collectively, these data indicate that cediranib is a potent pan-VEGFR kinase inhibitor with similar activity against c-Kit but is significantly less potent than PDGFR-α and PDGFR-β.
Similar articles
- KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, Guilbaud N, Hasegawa K, Kubo K, Fujiwara Y, Suzuki R, Kubo K, Shibuya M, Isae T. Nakamura K, et al. Cancer Res. 2006 Sep 15;66(18):9134-42. doi: 10.1158/0008-5472.CAN-05-4290. Cancer Res. 2006. PMID: 16982756 - Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler EK, Stoeltzing O, Lang SA. Taeger J, et al. Mol Cancer Ther. 2011 Nov;10(11):2157-67. doi: 10.1158/1535-7163.MCT-11-0312. Epub 2011 Sep 1. Mol Cancer Ther. 2011. PMID: 21885862 - Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents.
Nandi S, Dey R, Samadder A, Saxena A, Saxena AK. Nandi S, et al. Curr Med Chem. 2022;29(2):212-234. doi: 10.2174/0929867328666210303101345. Curr Med Chem. 2022. PMID: 33655823 Review. - Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Sakle NS, More SA, Dhawale SA, Mokale SN. Sakle NS, et al. Curr Drug Discov Technol. 2020;17(5):585-615. doi: 10.2174/1570163816666190808120843. Curr Drug Discov Technol. 2020. PMID: 31393251 Review.
Cited by
- Targeted anti-angiogenesis therapy for advanced osteosarcoma.
Zhang Q, Xia Y, Wang L, Wang Y, Bao Y, Zhao GS. Zhang Q, et al. Front Oncol. 2024 Aug 26;14:1413213. doi: 10.3389/fonc.2024.1413213. eCollection 2024. Front Oncol. 2024. PMID: 39252946 Free PMC article. Review. - Targeted Glioma Therapy-Clinical Trials and Future Directions.
Shikalov A, Koman I, Kogan NM. Shikalov A, et al. Pharmaceutics. 2024 Jan 11;16(1):100. doi: 10.3390/pharmaceutics16010100. Pharmaceutics. 2024. PMID: 38258110 Free PMC article. Review. - Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells.
Chrisochoidou Y, Roy R, Farahmand P, Gonzalez G, Doig J, Krasny L, Rimmer EF, Willis AE, MacFarlane M, Huang PH, Carragher NO, Munro AF, Murphy DJ, Veselkov K, Seckl MJ, Moffatt MF, Cookson WOC, Pardo OE. Chrisochoidou Y, et al. Cell Death Dis. 2023 Nov 8;14(11):725. doi: 10.1038/s41419-023-06240-x. Cell Death Dis. 2023. PMID: 37938546 Free PMC article. - Receptor Tyrosine Kinase: Still an Interesting Target to Inhibit the Proliferation of Vascular Smooth Muscle Cells.
Xiong Y, Wang Y, Yang T, Luo Y, Xu S, Li L. Xiong Y, et al. Am J Cardiovasc Drugs. 2023 Sep;23(5):497-518. doi: 10.1007/s40256-023-00596-3. Epub 2023 Jul 31. Am J Cardiovasc Drugs. 2023. PMID: 37524956 Review. - Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
Gaitskell K, Rogozińska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Gaitskell K, et al. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3. Cochrane Database Syst Rev. 2023. PMID: 37185961 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous